Skip to main content
N4 PHARMA PLC logo

N4 PHARMA PLC — Investor Relations & Filings

Ticker · N4P ISIN · GB00BYW8QM32 LEI · 213800I841D2RKMFK955 IL Professional, scientific and technical activities
Open in API
Filings indexed 840 across all filing types
Latest filing 2019-09-19 Regulatory Filings
Country GB United Kingdom
Listing IL N4P

About N4 PHARMA PLC

https://n4pharma.com/

N4 Pharma PLC is a specialist pharmaceutical company focused on the development of Nuvec®, its proprietary silica nanoparticle delivery system. This platform technology is designed to enhance the cellular delivery and potency of nucleic acid-based treatments, such as vaccines and cancer therapies. The company's primary focus is on applying Nuvec® to enable advanced therapies for oncology and infectious diseases. N4 Pharma's business model involves developing and out-licensing its technology to pharmaceutical and biotechnology partners to improve the performance of new and existing drugs.

Recent filings

Filing Released Lang Actions
Verona Pharma to Present Phase 2 Data with Ensifentrine Dry Powder Inhaler Formulation in COPD at European Respiratory Society International Congress 2019
Regulatory Filings Classification · 1% confidence The document is a press release issued by Verona Pharma plc on September 19, 2019, announcing that it will present positive interim data from a Phase 2 trial at the European Respiratory Society (ERS) International Congress on September 29, 2019. This is not a full financial report (like 10-K or IR), nor is it a transcript (CT) or a formal dividend notice (DIV). It is an announcement about upcoming presentation of clinical trial data and results, which falls under general investor communication regarding company progress. Since it is an announcement detailing upcoming presentation of results and scientific data, it is best classified as an Investor Presentation (IP) announcement or, more broadly, a general regulatory/investor announcement. Given the content focuses heavily on clinical trial data presentation details, 'Investor Presentation' (IP) is a strong fit, although it is an announcement *about* a presentation rather than the presentation itself. However, looking at the definitions, 'IP' is for the presentation itself. This document is a press release announcing the presentation details. Since it is a formal announcement of clinical data presentation, and not a standard earnings release (ER) or a general regulatory filing (RNS), and it is not short enough to strictly qualify as an RPA based on the 'Menu vs Meal' rule (it contains substantial background information), it is best categorized as a specific type of investor communication. Given the context of clinical data being presented, it is most closely related to an Investor Presentation (IP) or a general Regulatory Filing (RNS). Since it is a press release announcing scientific/clinical updates, and not a standard financial report, RNS (Regulatory Filings - fallback for miscellaneous announcements) is appropriate, but IP captures the essence better if we consider the subject matter. Let's re-evaluate against the definitions. It is an announcement of data presentation, not the presentation itself. It is not an Earnings Release (ER). It is a specific announcement about clinical trial data being shared at a conference. This type of announcement often falls under RNS if a more specific category isn't available. However, since the core subject is the presentation of data (which would typically be in an IP), and this is the announcement of that event, RNS is the safest general classification for a press release detailing scientific updates not covered by ER/IR/10-K. I will select RNS as the general regulatory announcement fallback for this specific type of corporate update.
2019-09-19 English
Interim Results
Interim / Quarterly Report Classification · 1% confidence The document is titled 'Interim Results' for N4 Pharma PLC for the six months ended 30 June 2019. It contains comprehensive financial statements, including a 'Condensed consolidated Statement of Comprehensive Income', and detailed management commentary regarding business operations, board changes, and future outlook. As it provides substantive financial data for a period shorter than a full fiscal year, it is classified as an Interim/Quarterly Report. H1 2019
2019-09-18 English
Holding(s) in Company TR-1: Standard form for notification of major holdings
Major Shareholding Notification Classification · 1% confidence The document is explicitly titled 'TR-1: Standard form for notification of major holdings' and contains structured tables detailing the acquisition or disposal of voting rights, the identity of the person subject to notification (Polar Capital LLP), the issuer (Verona Pharma Plc), and the resulting percentage of voting rights (5.03%). This format is characteristic of regulatory filings related to significant changes in share ownership thresholds, which corresponds to the Major Shareholding Notification category.
2019-09-09 English
Agreement for supply of SFX-01 for autism trial
M&A Activity Classification · 1% confidence The document begins with an 'RNS Number' and is dated September 5, 2019. It announces a specific corporate event: an 'Agreement for supply of SFX-01 for autism clinical trial' involving Evgen Pharma plc. The text explicitly mentions that this information is provided by RNS, the news service of the London Stock Exchange, and that it contains 'inside information' under MAR regulations. This structure—a brief announcement of a material event released via the London Stock Exchange's regulatory news service—is characteristic of a general regulatory filing that doesn't fit a more specific category like 10-K, ER, or DIV. Since it is a general regulatory announcement not covered by other specific codes (like DIRS, MANG, or CAP), the most appropriate fallback category is Regulatory Filings (RNS). The document length is moderate (6153 chars), but the content is purely an announcement of an agreement, not the full report itself.
2019-09-05 English
Verona Pharma to Present at H.C. Wainwright 21st Annual Global Investment Conference
Regulatory Filings Classification · 1% confidence The document is a press release dated September 3, 2019, announcing that the CFO of Verona Pharma plc will present at the H.C. Wainwright 21st Annual Global Investment Conference on September 10, 2019. This type of announcement, detailing executive participation in an external investment conference, is typically classified as an Investor Presentation (IP) or sometimes a general Regulatory Filing (RNS). Since the content focuses on updating investors about an upcoming presentation where company strategy and product pipeline (Ensifentrine) will be discussed, 'Investor Presentation' (IP) is the most fitting category, as it relates to investor outreach and presentation of company material, even if the presentation itself hasn't happened yet. It is not a formal regulatory report like 10-K or IR, nor is it a transcript or an earnings release.
2019-09-03 English
Update on SAS study
Legal Proceedings Report Classification · 1% confidence The document begins with an 'RNS Number' and is dated August 28, 2019. It contains an announcement from Evgen Pharma plc regarding a clinical trial milestone ('Last patient visit reached in the SAS study'). The text concludes with contact information for various parties and explicitly states, 'This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom.' This structure and explicit reference to RNS (Regulatory News Service) strongly indicate a general regulatory announcement that does not fit into the more specific categories like Earnings Release (ER), Interim Report (IR), or Director's Dealing (DIRS). Therefore, the most appropriate classification is Regulatory Filings (RNS). The document length (4878 chars) is not short enough to definitively trigger the RPA rule based on announcing a separate report, and it contains substantive operational news.
2019-08-28 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.